Drug intelligence / Profile preview

BK-5 exosomes

Development stage
Preclinical
Modality
Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration
Topical
01

Overview

BK-5 exosomes are extracellular vesicles derived from the lactic acid bacterium *Latilactobacillus sakei* strain BK-5, which was originally isolated from the flowers of *Aster koraiensis* (Korean starwort). These nanosized vesicles exhibit potent anti-inflammatory and skin-lightening activities. They work by suppressing the production of pro-inflammatory cytokines such as interleukin-6 (IL-6), interleukin-1β (IL-1β), and tumor necrosis factor-α (TNF-α), as well as inhibiting the expression of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2). In the context of skin health, BK-5 exosomes inhibit melanin biosynthesis by downregulating key melanogenesis-related proteins, including tyrosinase, TRP-1, TRP-2, and MITF. The underlying mechanism involves the inhibition of NF-κB and MAPK (including ERK, JNK, and p38) signaling pathways, making them potential candidates for pharmaceutical and cosmeceutical applications targeting inflammation and hyperpigmentation.

Other names
Latilactobacillus sakei BK-5 derived exosomesAster koraiensis-derived probiotic exosomesBK-5 extracellular vesiclesBK5 extracellular vesiclesBK 5 extracellular vesicles
02

Targets

TYRP1 (Tyrosinase-related protein 1)ERKIL-6 (Interleukin 6)NF-κBNOS2 (Nitric Oxide Synthase 2)TYR (Tyrosinase)JNK (Mitogen-activated protein kinase kinase kinase family)RK (Ribokinase)TNFA (Tumor necrosis factor alpha (soluble))TYRP2 (Tyrosinase-related Protein 2)IL1B (Interleukin-1 beta)

Beyond the preview

Go deeper on BK-5 exosomes.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on BK-5 exosomes.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call